scholarly journals Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

2018 ◽  
Vol 29 (4) ◽  
pp. 917-923 ◽  
Author(s):  
S. Banerjee ◽  
A.M. Oza ◽  
M.J. Birrer ◽  
E.P. Hamilton ◽  
J. Hasan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Study ◽  
Pegylated Liposomal Doxorubicin ◽  
Antibody Drug Conjugate ◽  
Open Label ◽  
Drug Conjugate ◽  
Open Label Phase ◽  
Antibody Drug

Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer

2006 ◽  
Vol 100 (2) ◽  
pp. 318-323 ◽  
Author(s):  
M.O. Nicoletto ◽  
C. Falci ◽  
D. Pianalto ◽  
G. Artioli ◽  
P. Azzoni ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Study ◽  
Advanced Ovarian Cancer ◽  
Pegylated Liposomal Doxorubicin

A multicenter open-label phase II study of the efficacy and safety of palbociclib a cyclin-dependent kinases 4 and 6 inhibitor in patients with recurrent ovarian cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5557-5557 ◽  
Author(s):  
Gottfried E. Konecny ◽  
Andrea Elisabeth Wahner Hendrickson ◽  
Aminah Jatoi ◽  
Jill K. Burton ◽  
Jill Paroly ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Ovarian Cancer ◽  
Efficacy And Safety ◽  
Open Label ◽  
Cyclin Dependent Kinases ◽  
Open Label Phase

Phase II Study of Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-Sensitive and Partially Platinum-Sensitive Metastatic Ovarian Cancer

2009 ◽  
Vol 19 (6) ◽  
pp. 1137-1141 ◽  
Author(s):  
B. L. Rapoport ◽  
D. A. Vorobiof ◽  
C. Slabber ◽  
A. S. Alberts ◽  
H. S. Hlophe ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Median Time ◽  
Median Survival ◽  
Phase Ii ◽  
Liposomal Doxorubicin ◽  
Phase Ii Study ◽  
Pegylated Liposomal Doxorubicin ◽  
Time To Progression ◽  
Overall Response ◽  
Platinum Sensitive

Objective:This phase II study assessed the activity and safety of pegylated liposomal doxorubicin (PLD) plus carboplatin in relapsed ovarian cancer (ROC).Method:Forty women with platinum-sensitive and partially platinum-sensitive ROC were treated with PLD 50 mg/m2plus carboplatin area under the curve 5 every 28 days in this South African multicenter study. All patients who completed 3 cycles of chemotherapy were evaluated for response. Primary outcome was response in the intent-to-treat population.Results:Complete response was 35%, and partial response was 32.5% (overall response, 67.5%). Median time-to-progression was 11.9 months, and median survival was 30.0 months. Overall response was higher in platinum-sensitive (81%) versus partially platinum-sensitive patients (53%), as were median duration of response, median time-to-progression, and median survival. Treatment was well tolerated, with no grade 4 nonhematologic toxicities. Grade 3/4 hematologic toxicities included leukopenia (58%), neutropenia (55%), and thrombocytopenia (43%).Conclusion:Pegylated liposomal doxorubicin plus carboplatin is well tolerated and active in the treatment of platinum-sensitive and partially platinum-sensitive ROC.

Sign in / Sign up

Export Citation Format

Share Document